Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 04, 2017 07:30 ET | Source: KemPharm

KemPharm and Genco Sciences Announce Technology Licensing Agreement to Develop Prodrug-Based Therapy for Potential Rare Pediatric Indications of Tourette’s Syndrome with ADHD

Agreement May Lead to Addition of New Drug Product Candidate and Indication to KemPharm’s Prodrug Development Pipeline CORALVILLE, Iowa, Oct. 04, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc....
September 20, 2017 07:30 ET | Source: KemPharm

KemPharm Files IND for KP484 for the Treatment of ADHD, An Investigational Prodrug of Methylphenidate

KP484 Designed to be a Predictably Dosed, Super-Extended Release, Methylphenidate Product CORALVILLE, Iowa, Sept. 20, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage...
September 12, 2017 07:15 ET | Source: KemPharm

KemPharm Announces FDRR Process Completion and Resubmission of the Apadaz™ NDA

FDA Has Assigned a PDUFA Action Date of February 23, 2018 Conference Call and Live Audio Webcast Today at 8:30 a.m. ET CORALVILLE, Iowa, Sept. 12, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc....
August 31, 2017 07:30 ET | Source: KemPharm

KemPharm to Present at the Rodman & Renshaw 19th Annual Global Investment Conference

CORALVILLE, Iowa, Aug. 31, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs,...
August 10, 2017 16:05 ET | Source: KemPharm

KemPharm, Inc. Reports Second Quarter 2017 Results

Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today at 4:30 p.m. ET Clinical Development & Regulatory Highlights: KP415.109 Pharmacokinetics Phase 1 Trial...
August 10, 2017 07:30 ET | Source: KemPharm

KemPharm Announces Preliminary Results from KP415 Pharmacokinetic Single and Multiple Dose Trial

Phase I Study Results Demonstrated Early Peak Exposure to d-Methylphenidate followed by Sustained Duration in both Single and Multiple Dose Settings CORALVILLE, Iowa, Aug. 10, 2017 (GLOBE...
August 08, 2017 07:30 ET | Source: KemPharm

KemPharm Announces Publication of Study of Intranasal Abuse of Hydrocodone Combination Products in Pharmacoepidemiology & Drug Safety

Study Confirms Intranasal Abuse of Hydrocodone/Acetaminophen by Adolescents & Adults may be a Significant Public Health Issue CORALVILLE, Iowa, Aug. 08, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc....
August 03, 2017 07:30 ET | Source: KemPharm

KemPharm to Present at Canaccord Genuity 37th Annual Growth Conference

CORALVILLE, Iowa, Aug. 03, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs,...
August 01, 2017 07:30 ET | Source: KemPharm

KemPharm, Inc. to Report Second Quarter 2017 Results

Conference Call and Live Audio Webcast with Slide Presentation Scheduled forAugust 10, 2017, 4:30 p.m. ET CORALVILLE, Iowa, Aug. 01, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a...
June 28, 2017 07:30 ET | Source: KemPharm

KemPharm Strengthens ADHD Prodrug Pipeline with Development of KP484, A New, Super-Extended Release ADHD Methylphenidate Product Candidate

KP415 End-of-Phase 1 Meeting with FDA Affirms KemPharm’s Development Plan and Potential NDA Submission as early as late 2018 Conference Call and Live Audio Webcast with Slide Presentation Scheduled...